Royal Bank of Canada
ATOS icon

Royal Bank of Canada’s Atossa Therapeutics ATOS Stock Holding History

Royal Bank of Canada’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Buy
644
+581
+922% +$3.68K ﹤0.01% 6560
2025
Q4 		$1K Buy
63
+13
+26% +$164 ﹤0.01% 6962
2025
Q3 		$1K Sell
50
-470
-90% -$5.8K ﹤0.01% 6948
2025
Q2 		$6K Sell
520
-649
-56% -$7.76K ﹤0.01% 6592
2025
Q1 		$12K Sell
1,169
-25
-2% -$304 ﹤0.01% 6082
2024
Q4 		$17K Buy
1,194
+310
+35% +$6.05K ﹤0.01% 6165
2024
Q3 		$20K Buy
884
+91
+11% +$1.84K ﹤0.01% 6099
2024
Q2 		$14K Buy
793
+790
+26,333% +$17.5K ﹤0.01% 6199
2024
Q1 		$0 Sell
3
-3
-50% -$48 ﹤0.01% 6994
2023
Q4 		$0 Sell
6
-7
-54% -$76 ﹤0.01% 7088
2023
Q3 		$0 Buy
13
+1
+8% +$15 ﹤0.01% 7065
2023
Q2 		$0 Buy
12
+11
+1,100% +$133 ﹤0.01% 7229
2023
Q1 		$0 Buy
+1
New +$11 ﹤0.01% 7054
2022
Q3 		– Sell
-1
Closed – – 7427
2022
Q2 		$0 Sell
1
-478
-100% -$7.53K ﹤0.01% 7352
2022
Q1 		$9K Sell
479
-1,115
-70% -$22.7K ﹤0.01% 6983
2021
Q4 		$38K Buy
1,594
+153
+11% +$5.6K ﹤0.01% 6521
2021
Q3 		$71K Buy
1,441
+347
+32% +$20.2K ﹤0.01% 5944
2021
Q2 		$104K Buy
1,094
+961
+723% +$50.9K ﹤0.01% 5579
2021
Q1 		$4K Buy
+133
New +$4.86K ﹤0.01% 7087
2018
Q2 		– Hold
0
– – – 6500
2018
Q1 		– Hold
0
– – – 6325
2017
Q4 		– Hold
0
– – – 6527
2017
Q3 		– Hold
0
– – – 6700
2017
Q1 		– Hold
0
– – – 6598
2016
Q4 		– Hold
0
– – – 6620
2016
Q3 		– Hold
0
– – – 6381
2016
Q2 		– Hold
0
– – – 6353
2015
Q4 		– Hold
0
– -$1K – 6621
2015
Q3 		– Hold
0
– – – 6460

Other funds holding ATOS

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royal Bank of Canada's ATOS Position: Q1 2026 in Review

Royal Bank of Canada increased its Atossa Therapeutics (ATOS) stake by 922% in Q1 2026, buying an estimated $3.68K and bringing the position to 644 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #6560.

Royal Bank of Canada first reported a position in ATOS in Q1 2021 and has held it in 19 quarters since. The position peaked at $104K in Q2 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Royal Bank of Canada held 644 shares of Atossa Therapeutics worth $3K as of Q1 2026.
  • Royal Bank of Canada bought 581 Atossa Therapeutics shares in Q1 2026, an estimated $3.68K.
  • Atossa Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6560 holding.
  • Royal Bank of Canada first reported a position in Atossa Therapeutics in Q1 2021 and has held it in 19 quarters since.
  • Royal Bank of Canada's Atossa Therapeutics position peaked at $104K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.